Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has initiated a study evaluating safety and efficacy of SARS-CoV-2 vaccination in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Zagouri, Flora, Liontos, Michalis, Sklirou, Aimilia D., Koutsoukos, Konstantinos, Markellos, Christos, Briasoulis, Alexandros, Papanagnou, Eleni-Dimitra, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165511/
https://www.ncbi.nlm.nih.gov/pubmed/34059088
http://dx.doi.org/10.1186/s13045-021-01099-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165511/
https://www.ncbi.nlm.nih.gov/pubmed/34059088
http://dx.doi.org/10.1186/s13045-021-01099-x

Ejemplares similares